Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study
Authors:
- Shannon GraboschSGShannon Grabosch
- George TsengGeorge Tseng
- Robert P. EdwardsRERobert P. Edwards
- Heather A. LankesHLHeather A. Lankes
- Kathleen MooreKMKathleen Moore
- Kunle OdunsiKOKunle Odunsi
- Anda VladAVAnda Vlad
- Tianzhou MaTMTianzhou Ma
- Mary StrangeMSMary Strange
- Joan BrozickJBJoan Brozick
- Amit LugadeALAmit Lugade
- Angela OmilianAOAngela Omilian
- 1 July 2017
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (1) , 137-145
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA 27469)
- Gynecologic Oncology Group Statistical and Data Center (CA 37517)
- NRG Oncology (1 U10CA180822)
- NRG (U1-CA180868)
- National Institutes of Health (1 P50 CA159981)
This publication has 21 references indexed in Scilit:
- Ports and complications for intraperitoneal chemotherapy deliveryBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patientsBMC Cancer, 2011
- Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complicationsGynecologic Oncology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaJournal of Translational Medicine, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2006
- Immunotherapy and chemotherapy — a practical partnershipNature Reviews Cancer, 2005
- Morphological effects of chemotherapy on ovarian carcinomaJournal of Clinical Pathology, 2002
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996